Molecular Partners AG
NASDAQ:MOLNBiotechnology
+$0.03 today
- Market cap
- $109.64M
- Beta
- 0.71
- P/E (TTM)
- -2.0
- EPS (TTM)
- -$1.55
Volume 0.00M
Average 0.00M
MOLN Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Molecular Partners AGNASDAQ: MOLN
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q1 FY2026 research & development of CHF 12.05M fell 9.1% year over year, behind the -1.7% change in trailing-twelve-month research & development. Sequentially, it rose 4.2% from the prior quarter. Over 3 fiscal years it compounded at -7.5% a year.
Context
- Research & development increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -9.1% toward the trailing-twelve-month pace of -1.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
CHF · from the income statement
- Latest · FY2025
- 40.19M CHF
- Year-over-year change
- -17.3%
- 4-year CAGR
- -7.8%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 40.19M | -17.3% |
| FY2024 | 2024-12-31 | 48.6M | -0.4% |
| FY2023 | 2023-12-31 | 48.78M | -3.9% |
| FY2022 | 2022-12-31 | 50.75M | -8.9% |
| FY2021 | 2021-12-31 | 55.72M | — |
Research & Development vs competitors
How MOLN compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -1.7% is the 3rd highest of 9, against a peer median of -23.2%.
- Over three fiscal years its annual growth of -7.5% compares with a peer median of +4.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $114.68M USD | -37.7% | -16.4% | 622.7% | |
| LTM Mar 2026 | $88.91M USD | -7.1% | -0.2% | — | |
| LTM Mar 2026 | $74.27M USD | +76.4% | +63.2% | — | |
| LTM Mar 2026 | $58.35M USD | -32.7% | +9.5% | — | |
| LTM Mar 2026 | CHF 46.97M CHF | -1.7% | -7.5% | — | |
| LTM Mar 2026 | $31.62M USD | -19.6% | +9.2% | 6022.3% | |
ELTXElicio Therapeutics, Inc. | LTM Mar 2026 | $23.84M USD | -29.5% | +13.5% | — |
| LTM Mar 2026 | $18.8M USD | -26.8% | -18.0% | 593.1% | |
| LTM Mar 2026 | $16.56M USD | +5.5% | -23.1% | 928.4% | |
| Peer median (excluding MOLN) | — | -23.2% | +4.5% | 775.6% | |
Competitors are the stored peer set for MOLN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 9.33M | 189.56M | 7.04M | 4.97M | 0 |
| Cost of Revenue | 55.72M | 50.75M | 47.84M | 47.5M | 2.58M |
| Gross Profit | (46.39M) | 138.81M | (40.81M) | (42.53M) | (2.58M) |
| Gross Margin | -497.2% | 73.2% | -579.8% | -855.8% | — |
| Research & Development | 55.72M | 50.75M | 48.78M | 48.6M | 40.19M |
| Selling, General & Admin | 16.91M | 21.82M | 19M | 17.16M | 14.87M |
| Operating Expenses | 72.75M | 72.94M | 20.3M | 18.68M | 50.89M |
| Depreciation & Amortization | 2.57M | 2.39M | 2.42M | 2.37M | 2.14M |
| EBITDA | (60.66M) | 119M | (59.52M) | (51.65M) | (59.49M) |
| EBITDA Margin | -650.2% | 62.8% | -845.6% | -1039.2% | — |
| Operating Income | (63.42M) | 116.61M | (61.11M) | (61.22M) | (58.12M) |
| Operating Margin | -679.7% | 61.5% | -868.3% | -1231.7% | — |
| Interest Income | 108.28K | 1.2M | 4.28M | 3.38M | 1.52M |
| Interest Expense | 608.14K | 648.12K | 49K | 25K | 18K |
| Other Income / Expenses | (365K) | 1.24M | (876K) | 7.18M | (3.53M) |
| Income Before Tax | (63.78M) | 117.85M | (61.98M) | (54.04M) | (61.65M) |
| Pre-Tax Margin | -683.6% | 62.2% | -880.7% | -1087.3% | — |
| Income Tax Expense | 2K | 0 | 0 | 2K | 2K |
| Net Income | (63.79M) | 117.85M | (61.98M) | (54.04M) | (61.65M) |
| Net Margin | -683.7% | 62.2% | -880.7% | -1087.4% | — |
| EPS (Basic) | (2.06) | 3.63 | (1.89) | (1.59) | (1.65) |
| EPS (Diluted) | (2.06) | 3.54 | (1.89) | (1.59) | (1.65) |
| Weighted Avg Shares | 31.01M | 32.47M | 32.77M | 34.03M | 37.27M |
| Weighted Avg Shares (Diluted) | 31.01M | 33.27M | 32.77M | 34.03M | 37.27M |
Molecular Partners AG
NASDAQ:MOLN
Intrinsic Alpha fair value
Locked
Current Price
$2.86
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.